Treats relapsing forms of multiple sclerosis (MS). Sold as Briumvi. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Ublituximab-Xiiy (sold as Briumvi), first approved Dec 28, 2022, with 0 new uses approved and 0 published complete response letters.
| Briumvi | Part B | $48.3M | +89% | 980 |
| Briumvi | Part D | $21.5M | +169% | 393 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)Relapsing Multiple Sclerosis, Multiple Sclerosis · TG Therapeutics, Inc. | — | Recruiting | May 30, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 28, 2022 | BriumviBLA 761238 · New molecular entity | Tg Therapeutics, Inc | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA